PMID- 33260499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201226
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Nov 28
TI  - Immune Regulation by Dendritic Cell Extracellular Vesicles in Cancer 
      Immunotherapy and Vaccines.
LID - 10.3390/cancers12123558 [doi]
LID - 3558
AB  - Extracellular vesicles (EVs) play a crucial role in intercellular communication 
      as vehicles for the transport of membrane and cytosolic proteins, lipids, and 
      nucleic acids including different RNAs. Dendritic cells (DCs)-derived EVs (DEVs), 
      albeit variably, express major histocompatibility complex (MHC)-peptide complexes 
      and co-stimulatory molecules on their surface that enable the interaction with 
      other immune cells such as CD8(+) T cells, and other ligands that stimulate 
      natural killer (NK) cells, thereby instructing tumor rejection, and counteracting 
      immune-suppressive tumor microenvironment. Malignant cells oppose this effect by 
      secreting EVs bearing a variety of molecules that block DCs function. For 
      instance, tumor-derived EVs (TDEVs) can impair myeloid cell differentiation 
      resulting in myeloid-derived suppressor cells (MDSCs) generation. Hence, the 
      unique composition of EVs makes them suitable candidates for the development of 
      new cancer treatment approaches including prophylactic vaccine targeting 
      oncogenic pathogens, cancer vaccines, and cancer immunotherapeutics. We offer a 
      perspective from both cell sides, DCs, and tumor cells, on how EVs regulate the 
      antitumor immune response, and how this translates into promising therapeutic 
      options by reviewing the latest advancement in DEV-based cancer therapeutics.
FAU - Fernandez-Delgado, Irene
AU  - Fernandez-Delgado I
AUID- ORCID: 0000-0002-4508-758X
AD  - Vascular Pathophysiology Department, Centro Nacional de Investigaciones 
      Cardiovasculares (CNIC), 28029 Madrid, Spain.
AD  - Immunology Service, Health Research Institute Hospital La Princesa (IIS-IP), 
      Faculty of Medicine, Universidad Autonoma de Madrid (UAM), 28006 Madrid, Spain.
AD  - Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), 
      Carlos III Health Institute, 28029 Madrid, Spain.
FAU - Calzada-Fraile, Diego
AU  - Calzada-Fraile D
AUID- ORCID: 0000-0001-7259-0757
AD  - Vascular Pathophysiology Department, Centro Nacional de Investigaciones 
      Cardiovasculares (CNIC), 28029 Madrid, Spain.
FAU - Sanchez-Madrid, Francisco
AU  - Sanchez-Madrid F
AD  - Vascular Pathophysiology Department, Centro Nacional de Investigaciones 
      Cardiovasculares (CNIC), 28029 Madrid, Spain.
AD  - Immunology Service, Health Research Institute Hospital La Princesa (IIS-IP), 
      Faculty of Medicine, Universidad Autonoma de Madrid (UAM), 28006 Madrid, Spain.
AD  - Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), 
      Carlos III Health Institute, 28029 Madrid, Spain.
LA  - eng
GR  - SAF2017-82886-R/Ministerio de Economia, Industria y Competitividad, Gobierno de 
      Espana/
PT  - Journal Article
PT  - Review
DEP - 20201128
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7761478
OTO - NOTNLM
OT  - cancer
OT  - dendritic cell (DC)
OT  - extracellular vesicles (EVs)
OT  - immunotherapy
OT  - oncopathogens
OT  - tumor-derived EVs
OT  - vaccines
COIS- The authors declare no potential conflict of interest.
EDAT- 2020/12/03 06:00
MHDA- 2020/12/03 06:01
PMCR- 2020/11/28
CRDT- 2020/12/02 01:01
PHST- 2020/10/15 00:00 [received]
PHST- 2020/11/18 00:00 [revised]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/02 01:01 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2020/12/03 06:01 [medline]
PHST- 2020/11/28 00:00 [pmc-release]
AID - cancers12123558 [pii]
AID - cancers-12-03558 [pii]
AID - 10.3390/cancers12123558 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Nov 28;12(12):3558. doi: 10.3390/cancers12123558.